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TRANSIENT BINDING EVENTS ARE A CHALLENGING ISSUE IN ENZYMOLOGY. HERE WE DEMOSTRATE A TIME-BASED ITC APPROACH 
TO HUMAN FLAVIN-CONTAINING MONOOXYGENASE 3, AN IMPORTANT DRUG METABOLISING ENZYME. WE MEASURE KINETIC 
CONSTANTS AND WE DEMONSTRATE HOW THIS APPROACH CAN BE EXPLOITED FOR MEASURING THE INHIBITON OF THE CONVERSION 
OF THE KEY SUBSTRATE TRIMETHYLAMINE TO TRIMETHYLAMINE N-OXIDE. 
 
 
Enzymes	   offer	   the	   possibility	   to	   study	   the	   details	   of	   the	   protein-­‐‑ligand	   interaction	   using	   a	   variety	   of	   techniques	  
among	   which	   X-­‐‑ray	   diffraction,	   nuclear	   magnetic	   resonance,	   surface	   plasmon	   resonance,	   fluorescence	   and	  
isothermal	  titration	  calorimetry1.	  In	  some	  cases	  ligand	  binding	  is	  transient	  and	  this	  can	  hamper	  the	  measurements	  
of	   detailed	   thermodynamic	   and	   kinetic	   parameters	   that	   are	   crucial	   for	   understanding	   the	   phenomenon.	   Here	  we	  
report	   an	   advanced	   calorimetric	   approach	   for	   the	   identification	   of	   enzyme-­‐‑ligand	   interactions	   in	   short-­‐‑lived	  
complexes.	   In	   order	   to	   demonstrate	   its	   applicability,	   we	   have	   used	   the	   recombinant	   human	   flavin-­‐‑containing	  
monooxygenase	  3	  (hFMO3)	  as	  test-­‐‑case.	  The	  reaction	  mechanism	  of	  hFMO3	  involves	  the	  reduction	  by	  NADPH	  and	  
the	   formation	   of	   a	   hydroperoxy	   intermediate	   FAD	   that	   can	   perform	   a	   nucleophilic	   attack	   on	   the	   target	   substrate	  
acting	   like	   a	   “loaded	   gun”2,3.	   This	   involves	   a	   short-­‐‑lived	   binding	   of	   the	   substrate	   to	   the	   enzyme	   only	   for	   the	   time	  
required	   by	   FMO3	   to	   oxidize	   a	   large	   number	   of	   N-­‐‑	   or	   S-­‐‑	   soft	   nucleophiles	   to	   the	   corresponding	   oxide	   products	  
through	   the	   insertion	   of	   one	   atom	   of	   oxygen	   into	   the	   substrate4,5.	   hFMO3	   is	   responsible	   for	   the	   physiological	  
transformation	  of	   trimethylamine	  (TMA)	   to	   trimethylamine	  N-­‐‑oxide	  (TMAO)6.	  Recent	  works	  have	  demonstrated	  a	  
clear	  correlation	  between	  high	  levels	  of	  TMAO	  in	  the	  body	  and	  cardiovascular	  diseases7-­‐‑12.	  The	  new	  findings	  place	  
FMO3	   in	   the	   context	   of	   atherosclerosis	   and	   cardiovascular	   disease	   and	   efforts	   are	   being	   made	   to	   elucidate	   the	  
regulation	  and	  the	  molecular	  actors	  involved	  in	  the	  process13.	  Therefore	  methods	  for	  the	  assessment	  of	  the	  enzyme	  
function	   in	   terms	   of	   catalytic	   activity	   are	   strongly	   needed	   as	   well	   as	   ways	   to	   test	   the	   inhibition	   of	   the	   TMAO	  
synthesis	  reaction.	  Here	  we	  report	  the	  first	  kinetic	  study	  of	  hFMO3	  by	  time-­‐‑based	  ITC.	  	  
The	   ITC	   substrate	   conversion	   experiment	   is	   carried	   out	   using	   NADPH	   reduced	   enzyme	   in	   the	   sample	   cell.	   Upon	  
reduction	  with	   NADPH	   the	   enzyme	   binds	   oxygen	   and	   can	   either	   perform	  monooxygenation	   in	   the	   presence	   of	   a	  
suitable	  substrate	  or	  decay	  with	  concurrent	  production	  of	  H2O214.	  The	  basal	  uncoupling	  reaction	  always	  occurs,	  but	  
the	  ITC	  system	  is	  equilibrated	  initially	  with	  the	  reduced	  enzyme,	  so	  the	  ΔPower	  (ΔP)	  between	  the	  cells	  is	  maintained	  
throughout	  the	  whole	  experiment	  and	  upon	  substrate	  addition	  only	  product	  formation,	  amine	  oxidation	  (Scheme1,	  
reaction	  3),	   is	   actually	  detected	  whereas	   the	  uncoupling	   reaction	   is	   continuously	   compensated	  by	   the	   instrument	  











By	  operating	  in	  kinetics	  mode,	  the	  heat	  flow	  variation	  of	  time-­‐‑based	  ITC	  can	  be	  directly	  correlated	  to	  the	  rate	  of	  the	  
reaction.	  The	  data	  obtained	  after	  the	  measurement	  are	  the	  offset	  of	  the	  heat	  plot	  from	  the	  starting	  baseline	  (Scheme	  
2),	  and	  they	  repre-­‐‑sent	  the	  thermal	  power	  (μcal/s)	  provided	  by	  the	  calorimeter	  to	  the	  sample	  cell	  to	  compensate	  for	  
the	   heat	   change.	   The	   thermal	   power	   is	   proportional	   to	   the	   heat	   flow	   that	   is	   taking	   place	   in	   the	   sample	   cell	   over	  
time15.	  Michaelis-­‐‑Menten	   parameters	   are	   then	   derived	   by	   using	   the	   total	  molar	   enthalpy	   (ΔH)	   and	   the	   heat	   flow	  
(dQ/dt)	  calculated	  at	  several	  substrate	  concentrations.	  In	  two	  different	  experiments,	  firstly	  the	  heat	  generated	  from	  
the	   total	   conversion	   of	   the	   substrate	   is	   measured	   and	   secondly	   the	   heat	   production	   is	   measured	   at	   increasing	  
substrate	  concentrations	  using	  the	  variation	  of	  heat	  calculated	  from	  the	  first	  experiment	  to	  fit	  the	  experimental	  data	  
(Scheme	  2).	  
	  
Scheme	  1	   	  Reactions	  carried	  out	  by	  hFMO3.	   	   1)	   hFMO3	  oxidizes	  NADPH,	  2)	  binds	  
oxygen	   forming	   hydroperoxyflavin	   and	   3)	   oxidizes	   the	   substrate.	   The	   ITC	   setup	  




University of Turin’s Institutional Research Information System and Open Access Institutional Repository 
 
	  
More specifically, the experimental setup for measuring hFMO3 activity is initiated by the injection of the substrate into the sample 
cell containing the reduced enzyme at a constant temperature. As soon as catalysis occurs, the amount of heat released by the reaction 
is measured and this value is directly related to the amount of substrate that is transformed into the product. In this work either 
low/mid or no feedback modes were employed for the measurement of enzyme kinetics: the no feedback mode was used in the first 
stage of the experimental setup to highlight major differences between full reaction and selected controls. Low/mid feedback mode 
was then used as the optimal setup for all the reactions that yielded kinetic parameters and when a competing substrate was used. The 
specific feedback mode can be optimized for each experiment in order to maximize the amplitude of the phenomenon to be observed, 
but it does not impact the result of the experiment16. A typical no feedback mode time-based ITC single injection experiment, in 
which the instrument does not compensate for the changes in temperature that occur during the experiment, is shown in Figure 1. 
Under aerobic conditions, hFMO3 oxidizes the substrate as indicated by the presence of a strong negative enthalpic peak when 
trimethylamine is added in the cell (Fig. 1 filled circles). The exchanged heat, as expected, is stronger in the presence of enzyme 
NADPH and the substrate as compared to simple enzyme reduction by NADPH. Three different control experiments were performed 
to prove the loaded gun mechanism. In control 1 the injection of TMA in the cell results in a positive enthalpic contribution due to 
the dilution of the substrate in the cell which contains only the phosphate buffer and the NADPH cofactor. The plot of the heat 
change over time shows how, immediately after the maximum of about 0.5 µcal/s is achieved the curve goes back to the original 




In control 2, NADPH is titrated in the cell containing the phosphate buffer. The titration yields a minimal change in the baseline of 
about 0.2 µcal/s and subsequent stabilization (Fig. 1 thin curve). In control 3 NADPH is titrated in the cell that contains the enzyme 
and the phosphate buffer (Fig. 1 empty circles). In this case a strong negative peak reaching a minimum of 1.0 µcal/s is detected and 
a slow return to the original baseline is completed only after 200 minutes. These data are in line with a complete oxidation of the 
NADPH in the cell and provide the right setup for evaluating the effect of the FMO3 loaded gun on the substrate. Indeed, when the 
NADPH reduced enzyme in the cell is titrated with benzydamine a positive enthalpic peak is detected (Fig.1 filled circles), due to the 
heat of dilution of the substrate in the buffer, followed by a strong negative minimum down to a value of about -2.2 µcal/s. During 
the enzymatic reaction, a faster return to the original baseline is detected. hFMO3 acts as a loaded gun attacking the substrate and 
accelerating the return to its oxidized state and the release of product and NADP+. The results are fully in line with previously 
published stopped-flow data indicating reduction of the enzyme followed by formation of the hydroperoxy intermediate with rate 
Scheme	  2	  	  Principles	  of	  time-­‐‑based	  ITC	  for	  Km	  and	  kcat	  determination	  for	  hFMO3.	  1)	  
Reduced	  enzyme	  reacts	  with	  the	  substrate	  2)	  Enthalpy	  of	  the	  reaction	  is	  determined	  
by	   single-­‐‑injection	   mode	   and	   kinetics	   calculated	   by	   multiple-­‐‑injections	   mode.	   3)	  
Data	   analysis	   is	   performed.	   ΔH	   is	   enthalpy.	   Q	   is	   heat,	   t	   is	   time,	   n	   are	   moles	   of	  
product,	  V	  is	  volume,	  v	  is	  reaction	  rate,	  	  P	  is	  power,	  [P]	  is	  product	  concentration
Fig.	   1	   No	   feedback	   mode	   time-­‐‑based	   ITC	   single	   injection	   experiments.	   NADPH	  
reduced	  hFMO3	  +	  TMA	  injection	  (filled	  circles).	  NADPH+TMA	  injection	  (thick	  curve),	  
Buffer	  +	  NADPH	  injection	  (thin	  curve),	  hFMO3	  +	  NADPH	  injection	  (empty	  circles)	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acceleration when the substrate is also present14,17-20. The total molar enthalpy and the heat flow occurring during the reaction for 
trimethylamine ΔH was found to be -49.5 kcal/mol. In order to fully understand how responsive the time-based ITC system is to 
relative changes in enzyme concentration, four different experiments in multiple injections mode were performed with hFMO3 
concentrations in the range 1.2-9.6 µM hFMO3 (Figure 2).  
 
	  
The data show how time-based ITC measures variations with respect to the initial baseline values with as little as 1.2 µM of 
hFMO3.Other well-known substrates of hFMO3 such as benzydamine, ethionamide and methimazole were also tested (Figure S1, 
Figure S2). Also in this case multiple injection mode was employed to reach the maximum enzyme velocity upon subsequent 
injections without letting the system re-equilibrate back to the original baseline. All the substrates tested showed a typical Michaelis-
Menten behaviour and no product inhibition was detected. Overall heat change due to product formation was significant for all the 
substrates studied, leading to a low signal to noise ratio. The results reported in Table 1 are found to be fully in line with previously 
reported data for other methods21-24 except for ethionamide that exhibited a significantly lower Km value, but in this specific case the 
only available reference  (Henderson et al., 200824) data were obtained at the non-physiological of pH 9.5, so they cannot directly 
comparable to our setup.  











trimethylamine	   16.8±1.2	   28.021	   42.0±5.6	   36.321	  
benzydamine	   111.0±4.6	   80.022	   43.0±6.1	   36.022	  
methimazole	   15.9±1.3	   35.023	   23.7±2.9	   50.023	  
ethionamide	   35.0±2.4	   336.024	   13.1±0.6	   58.424	  
 
The ΔH is the sum of all heats that are exchanged during the observed reaction and is dependent on the molar enthalpy of all the 
processes involved and, when existing, upon proton uptake/release from the buffer which normally corresponds to proton acquisition 
from the buffer solution. The measured ΔH can therefore be defined as apparent (ΔHapp), as this includes the intrinsic ΔHint of the 
reaction, as well as the ionization enthalpy of the buffer (ΔHion) for the number of exchanging protons (n) leading to the 
relationship16: ΔHapp = ΔHint + nΔHion. In order to calculate the ΔHint the reduced enzyme was titrated with TMA in 3 different 
buffers, phosphate, HEPES and TRIS, each with a specific heat of ionization. Data fitting yielded the abstraction of a single proton 
from the buffer solution and an intrinsic ΔHint of -31.4 kcal/mol (Figure 3, S3).   
 
	  
Fig.	  3	  Determination	  of	  the	  intrinsic	  ΔH	  of	  the	  reaction	  measured	  by	  time-­‐‑based	  ITC	  
single	  injection	  mode.	  Conditions	  are	  4.8	  μM	  hFMO3,	  1.2	  mM	  NADPH,	  10	  µM	  TMA	  in	  
20	   mM	   HEPES	   (black	   curve),	   TRIS	   (red	   curve)	   or	   phosphate	   (green	   curve)	   buffer,	  
25°C,	  300	  rpm	  stirring,	  low	  feedback	  mode,	  titration	  volume	  2	  µl.	  
Fig.2	  Multiple	  injections	  time-­‐‑based	  ITC	  measurements	  of	  TMA	  (2	  µl	  of	  30	  µM)	  in	  50	  
mM	  KPi	  buffer	  pH	  7.4	  containing	  	  hFMO3	  (1.2-­‐‑9.6	  µM)	  and	  1.2	  mM	  NADPH,	  25°C,	  300	  
rpm	  stirring,	  mid-­‐‑feedback	  mode,	  120	  seconds	  spacing	  between	  each	  injection.	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In the last step of the catalytic cycle of hFMO3 the hydroperoxyflavin FAD-OOH decays performing monooxygenation on the 
substrate molecule. After monooxygenation the hydroxyflavin FAD-OH is converted back to original oxidized FAD from with 
subsequent production of H2O and release of NADP+. H2O is formed upon proton abstraction from the buffer solution. As there are 
no data available in literature for this measurement, these data represent the first direct evidence of proton exchange during the 
enzymatic reaction. FMO is known to work better at pH above 8.025. In order to test the pH dependent activity for hFMO3 several 
single injections of TMA were performed in the pH range between 7.0 and 9.0 (Fig. 4). The results clearly show how the enzyme is 
more active above pH 8.0 as demonstrated by both the increased heat exchanged and the total turnover of the substrate at pH 8.4 
compared to pH 7. 
 
	  
TMAO was recently found as one of the metabolites associated to cardiovascular disease26. One of the possible strategies to reduce 
the body levels of TMAO is to inhibit the FMO3 function. To do so, biochemical methodologies must be developed that address 
directly the formation of TMAO. Methimazole is a very good competing substrate27 for both N- or S- oxidation that is also very often 
referred to as a competitive inhibitor of the enzyme. We tested the inhibitory effect of methimazole on TMA metabolism using a set 




When increasing concentration of methimazole are included in the ITC cell and constant concentration of TMA is titrated the 
negative enthalpic peak decreases indicating that the competing substrate is contrasting the conversion of TMA to TMAO. A plot of 
the heat as a function of methimazole yields an IC50 concentration28 of 12.5µM (Figure 5B). 
In conclusion, to date the only direct binding of a ligand to hFMO3 using ITC has been carried out with the oxidized NADP 
cofactor17. Here we show for the first time how time-based ITC can address fundamental enzymology processes by operating in 
kinetic mode, allowing us to measure transient ligand binding. The method was demostrated for different substrates such as 
trimethylamine, benzydamine, methimazole and ethionamide. Most interestingly, given the importance of identifying potential 
inhibitors of TMAO synthesis in humans, we have demonstrated how the action of a known competing substrate of hFMO3, 
methimazole, can be detected and directly correlated to an IC50 concentration. Upon molecular docking screening and 
characterization29, testing of new inhibitors of hFMO3 can now be envisioned and perhaps a non-substrate molecule that works in 
kinetics mode could also potentially be tested in classic binding experiments.  Finally, the methodology developed in this work can 
be extended to other enzymes that bear similar mechanisms of action or that normally are difficult to characterize given the transient 
nature of the binding events occurring between enzyme and substrate or inhibitor. 
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Fig.	  4	  pH	  dependence	  of	  hFMO3	  activity	  measured	  by	  time-­‐‑based	  ITC	  single	  injection	  
mode.	   Conditions	  are	   4.8	  μM	  hFMO3,	  1.2	  mM	  NADPH,	  10	  µM	  TMA	   in	  50	  mM	  TRIS	  
buffer,	  25°C,	  300	  rpm	  stirring,	  low	  feedback	  mode,	  titration	  volume	  2	  µl.	  	  
a) b) 
Fig.	   5	   Inhibition	   of	   hFMO3	   activity	   measured	   by	   single	   injection	   time-­‐‑based	   ITC	  
mode.	   A)	   Conditions	   are	   4.8	   μM	   hFMO3,	   1.2	   mM	   NADPH,	   30	   µM	   TMA,	   0-­‐‑128	   µM	  
methimazole	  in	  50	  mM	  phosphate	  buffer,	  pH	  7.4	  25°C,	  300	  rpm	  stirring,	  low	  feedback	  
mode,	  titration	  volume	  2	  µl.	  B)	  	  Enthalpy	  values	  obtained	  in	  the	  presence	  of	  different	  
concentrations	  of	  inhibitor	  were	  fitted	  using	  a	  sigmoidal	  function.	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